# Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

> **NCT01130025** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 900 (actual)

## Conditions studied

- Venous Thromboembolism

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Innohep®

## Key facts

- **NCT ID:** NCT01130025
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-05
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130025, "Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01130025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*